Related Experiment Videos
Three-monthly GnRH agonist (buserelin) for prostatic cancer
British Journal of Urology
|January 1, 1990
Summary
A new 3-monthly buserelin injection effectively suppresses testosterone in advanced prostate cancer patients. This long-acting formulation offers patient and clinician advantages over shorter-acting options.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Advanced prostate cancer requires long-term androgen deprivation therapy.
- Current gonadotropin-releasing hormone (GnRH) analogue formulations necessitate frequent administration.
- There is a need for improved delivery systems for sustained hormone suppression.
Purpose of the Study:
- To evaluate a novel 3-monthly slow-release buserelin depot injection for advanced prostate cancer.
- To assess the pharmacokinetic and pharmacodynamic profile of the new formulation.
- To compare its efficacy in testosterone suppression with existing treatments.
Main Methods:
- A new 3-monthly slow-release buserelin depot injection was administered.
- Evaluated in 4 patients with advanced prostate cancer on prior shorter-acting depots.
- Also assessed in 7 previously untreated patients.
- Urinary buserelin concentrations and serum testosterone levels were monitored.
Main Results:
- Steady-state urinary buserelin concentrations were achieved by week 3 and maintained for 3 months.
- Serum testosterone remained suppressed in the castrate range throughout the study in previously treated patients.
- Testosterone suppression into the castrate range occurred within 7-14 days in new patients.
Conclusions:
- The 3-monthly buserelin depot injection provides sustained testosterone suppression.
- This formulation demonstrates advantages for patient convenience and clinical management.
- The new formulation warrants further clinical investigation for advanced prostate cancer treatment.